The U.S. Food and Drug Administration’s approval of vepdegestrant on 1 May for patients with ESR1-mutated, ER-positive and HER2-negative advanced breast cancer represents a landmark moment in pharmaceutical science, as it is the world’s first therapy built on PROTAC (proteolysis-targeting chimera) technology to receive regulatory clearance. Rather than merely blocking a harmful protein’s activity, as conventional drugs do, vepdegestrant is designed to physically destroy the disease-causing protein altogether — a fundamentally different therapeutic philosophy that researchers have spent more than two decades developing.
This development matters profoundly for global public health because it opens a viable pathway for treating diseases involving proteins that have historically been considered “undruggable” using conventional small-molecule inhibitors. For India, which carries a significant burden of breast cancer cases and is simultaneously building indigenous biotechnology and pharmaceutical research capacity, understanding this technology’s mechanism and its future applicability is essential.
💡 Get AI-powered exam prep on your phone!
For UPSC and SSC aspirants, this topic falls squarely within GS-III (Science and Technology, particularly biotechnology and health innovation) and is a recurring theme in Prelims questions on new drug technologies and Mains questions on India’s pharmaceutical and biotech ecosystem.
Background and Context
Five Important Key Points
- Vepdegestrant, jointly developed by Arvinas and Pfizer, became the first PROTAC-based drug in the world to receive FDA approval, specifically for patients with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer.
- PROTAC stands for Proteolysis-Targeting Chimera, a technology in which a single engineered molecule binds simultaneously to a target disease-causing protein and to an E3 ligase enzyme, thereby tagging the target protein for complete degradation by the cell’s own protein-disposal machinery.
- Unlike conventional inhibitor drugs, which must occupy a protein’s active site continuously and therefore struggle against certain mutations, PROTAC molecules act catalytically, meaning a single PROTAC molecule can degrade multiple copies of the target protein over time.
- More than 40 PROTAC-based candidates are currently in various stages of clinical trials globally, targeting cancers as well as neurodegenerative diseases, inflammatory conditions, and other disorders where the underlying disease protein has proved abnormally difficult to target using traditional small-molecule drugs.
- The FDA’s approval pathway for vepdegestrant, based on results from a Phase 3 trial enrolling 624 patients previously treated with CDK4/6 inhibitors and endocrine therapy, is expected to shorten future development timelines for other PROTAC candidates now entering late-stage testing.
The Scientific Mechanism Behind PROTAC Technology
PROTAC molecules operate through a two-headed design: one end of the molecule binds to the disease-causing target protein, while the other end binds to an E3 ubiquitin ligase, an enzyme integral to the cell’s protein degradation pathway. By bringing these two components into close physical proximity, the PROTAC molecule causes the target protein to be “tagged” with ubiquitin, marking it for destruction by the proteasome — the cell’s internal protein-recycling system. Because PROTAC molecules act as catalysts rather than being consumed in the process, they can be effective at much lower concentrations than conventional inhibitors, in principle reducing dosage requirements and associated side effects.
Historical Development Timeline
The concept of targeted protein degradation was first proposed by research teams at Yale University and Caltech in 2001, but it took the biotechnology company Arvinas, founded specifically to commercialise this science, to bring the first drug candidates into human clinical trials starting around 2019. Vepdegestrant’s approval in 2026, following roughly seven years of clinical development after Arvinas’s earliest trials, illustrates both the promise and the extended timelines still required to translate this novel mechanism into approved medicine.
Potential Applications Beyond Cancer
Beyond oncology, PROTAC technology is being actively explored for neurodegenerative diseases such as Parkinson’s and Alzheimer’s, where misfolded or aggregated proteins are central to disease progression, as well as for inflammatory and autoimmune conditions. Because PROTAC drugs can target proteins lacking a suitable binding pocket for traditional inhibitors, they open therapeutic possibilities for an estimated majority of disease-associated proteins in the human proteome that remain “undruggable” by conventional means.
Challenges to Overcome
Despite this promise, PROTAC molecules face significant developmental challenges. They are generally larger and structurally more complex than traditional small-molecule drugs, which complicates oral bioavailability and gut absorption. Resistance mechanisms can also emerge over time, for instance through cellular adaptations that reduce E3 ligase availability or alter the target protein’s structure. Further clinical research is required to fully understand long-term safety, optimal dosing schedules, and comparative effectiveness against existing standard-of-care treatments across diverse patient populations.
Relevance for India’s Healthcare and Biotech Ecosystem
India carries one of the highest burdens of breast cancer among developing nations, and access to cutting-edge targeted therapies like vepdegestrant will likely remain limited by cost in the near term, given that PROTAC drugs are complex to manufacture. This underscores the importance of India’s own biotechnology innovation ecosystem, supported through schemes such as the Biotechnology Industry Research Assistance Council (BIRAC) and the National Biopharma Mission, in eventually developing affordable indigenous alternatives or generic pathways once patent protections expire.
Way Forward
India should prioritise capacity-building in advanced drug-discovery technologies, including targeted protein degradation platforms, through greater public investment in translational research institutions and stronger industry-academia collaboration. Regulatory frameworks under the Central Drugs Standard Control Organisation (CDSCO) will also need to evolve rapidly to handle the unique safety and manufacturing considerations posed by these next-generation biologic and chimeric therapies.
Relevance for UPSC and SSC Examinations
This topic is relevant to GS-III (Science and Technology — biotechnology, health innovation, and indigenisation of drug development). For SSC, it is useful under General Science and current developments in medical technology. Key terms: PROTAC (Proteolysis-Targeting Chimera), E3 ubiquitin ligase, targeted protein degradation, ESR1 mutation, CDK4/6 inhibitors, BIRAC, National Biopharma Mission, CDSCO.